[11C]-labeled metformin distribution in the liver and small intestine using dynamic positron emission tomography in mice demonstrates tissue-specific transporter dependency

Diabetes

Volumn 65, Issue 6, 2016, Pages 1724-1730

  Jensen, Jonas B ^a,b   Sundelin, Elias I ^a   Jakobsen, Steen ^b   Gormsen, Lars C ^b   Munk, Ole L ^b   Frøkiær, Jørgen ^a,b   Jessen, Niels ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CIMETIDINE; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PYRIMETHAMINE; ANTIDIABETIC AGENT; ORGANIC CATION TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; BILE SECRETION; BILIARY EXCRETION; BLOOD; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG UPTAKE; FEMALE; KIDNEY; LIVER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMALL INTESTINE; TARGET ORGAN; TISSUE SPECIFICITY; ANIMAL; METABOLISM; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; HYPOGLYCEMIC AGENTS; INTESTINE, SMALL; LIVER; METFORMIN; MICE; ORGANIC CATION TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84969800847     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0032     Document Type: Article

References (24)

1. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its antidiabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348:607-614
2. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-2369
3. Duca FA, Côté CD, Rasmussen BA, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med 2015;21:506-511
4. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned protonstimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007;35:1956-1962
5. Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005;70:1851-1860
6. Schweifer N, Barlow DP. The Lx1 gene maps to mouse chromosome 17 and codes for a protein that is homologous to glucose and polyspecific transmembrane transporters. Mamm Genome 1996;7:735-740
7. Green RM, Lo K, Sterritt C, Beier DR. Cloning and functional expression of a mouse liver organic cation transporter. Hepatology 1999;29:1556-1562
8. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-1431
9. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-515
10. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008;83:273-280
11. Hiasa M, Matsumoto T, Komatsu T, Moriyama Y. Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. Am J Physiol Cell Physiol 2006;291:C678-C686
12. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 2009;75:1280-1286
13. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012;22:820-827
14. Hume WE, Shingaki T, Takashima T, et al. The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. Bioorg Med Chem 2013;21:7584-7590
15. Shingaki T, Hume WE, Takashima T, et al. Quantitative evaluation of mMate1 function based on minimally invasive measurement of tissue concentration using PET with [(11)C]metformin in mouse. Pharm Res 2015;32:2538-2547
16. Jakobsen S, Busk M, Jensen JB, et al. A PET tracer for renal organic cation transporters, 11C-metformin: radiosynthesis and preclinical proof-of-concept studies. J Nucl Med 2016;57:615-621
17. Testa A, Zanda M, Elmore CS, Sharma P. PET tracers to study clinically relevant hepatic transporters. Mol Pharm 2015;12:2203-2216
18. Maguire RP, Leenders KL. Cerebral blood flow-single-tissue-compartment model. In PET Pharmacokinetic Course Manual. Maguire RP, Leenders KL, Eds. University of Groningen, Groningen, The Netherlands and McGill University, Canada 2003, Chapter 4, p. 29-32
19. Ito S, Kusuhara H, Yokochi M, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2012;340:393-403
20. Stepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 2002;30:861-868
21. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 2005;102:17923-17928
22. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos 2012;40:1170-1177
23. Chen EC, Liang X, Yee SW, et al. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. Mol Pharmacol 2015;88:75-83
24. Ito S, Kusuhara H, Kuroiwa Y, et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010;333:341-350